Ionis Pharmaceuticals (IONS) grants 19,350 options to EVP HR chief

Rhea-AI Filing Summary

Ionis Pharmaceuticals reported a routine equity grant to executive Shannon L. Devers, its EVP and Chief Human Resources Officer. On 01/02/2026, Devers received a non-qualified stock option to buy 19,350 shares of Ionis common stock at an exercise price of $79.67 per share under the company’s Amended and Restated 2011 Equity Incentive Plan.

The option was not exercisable for any shares on the grant date. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, ending before the option’s expiration on 01/01/2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devers Shannon L.

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CA 92010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Human Resources Ofc

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$79.67	01/02/2026		A		19,350		01/02/2027(1)	01/01/2036	Common Stock	19,350	$0.0	19,350	D

Explanation of Responses:

1. Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

	By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ionis Pharmaceuticals (IONS) disclose for Shannon L. Devers?

Ionis Pharmaceuticals disclosed that Shannon L. Devers, its EVP and Chief Human Resources Officer, received a grant of 19,350 non-qualified stock options on 01/02/2026.

What are the key terms of the 19,350 stock options granted by Ionis (IONS)?

The grant is a non-qualified stock option for 19,350 shares of Ionis common stock with an exercise price of $79.67 per share and an expiration date of 01/01/2036.

How do the granted Ionis (IONS) stock options to Shannon Devers vest?

The option was exercisable for 0 shares on 01/02/2026. 25% of the shares vest and become exercisable on 01/02/2027, and the remaining shares vest in 36 equal monthly installments over the next three years.

Is the Ionis Pharmaceuticals (IONS) stock option grant to Shannon Devers held directly or indirectly?

The filing shows the 19,350 stock options as held with direct ownership by Shannon L. Devers.

Under which plan were the Ionis (IONS) stock options to Shannon Devers granted?

The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

How many derivative securities does Shannon Devers hold after this Ionis (IONS) transaction?

After this grant, Shannon L. Devers beneficially owns 19,350 derivative securities in the form of non-qualified stock options.